Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

Decreased breast cancer survival associated with high TRAIL-R2 expression

Yale University : 25 July, 2005  (New Product)
High expression of TRAIL-R2, a cell surface receptor that triggers cell death, has been shown to be associated with a decrease in the survival rates of breast cancer patients according to a study published by Yale Cancer Center researchers in Clinical Cancer Research.
High expression of TRAIL-R2, a cell surface receptor that triggers cell death, has been shown to be associated with a decrease in the survival rates of breast cancer patients according to a study published by Yale Cancer Center researchers in Clinical Cancer Research.

Analyzing 20-year follow-up data from breast cancer patients, using an automated quantitative analysis system to review tissue microarray specimens, the researchers identified increased intensity of TRAIL receptor expression. AQUA scores were correlated with clinical and pathologic variables. In addition, TRAIL-R1 and TRAIL-R2 expression were both studied on 95 unmatched normal breast specimens.

Yale Researchers concluded that while TRAIL-R1 expression was not associated with survival, high TRAIL-R2 expression strongly correlated with decreased survival.

'A number of TRAIL receptor targeting therapies are currently in clinical development. As with other targeted therapies, it is important to determine which patients are more likely to respond to these therapies,' said Harriet Kluger, MD, author on the study and Assistant Professor of Medicine in the Section of Medical Oncology at Yale School of Medicine. 'AQUA allows us to stratify patients based on expression levels of drug targets in an automated, unbiased fashion. This will help us reach our ultimate goal of practicing personalized medicine, by treating patients based on characteristics of individual tumors.'

The AQUA system measures and localizes specific variations in protein expression within tissue automatically, with a high level of precision. The multi-tissue proteomic analysis system combines fluorescence-based imaging with automated microscopy and high-throughput tissue microarray technologies. HistoRx has exclusively licensed the AQUA technology that was developed by David Rimm, M.D., Ph.D. and Robert Camp, M.D., of the Yale University School of Medicine and Yale Cancer Center.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo